Japan-based Shionogi & Co., Ltd. (Shionogi) has formed a strategic alliance with digital therapy venture Akili to develop and commercialize digital therapeutics in Asia. The two report in a joint press release that Akili will create first-of-its-kind international digital medicine development and commercial platform. Shionogi, a $3 billion revenue Japanese pharma founded in 1878, will oversee advanced digital therapy clinical development, sales and marketing for ADHD and Autism Spectrum Disorder digital therapeutics in Japan and Taiwan commercialization valued up to $125 million. Shionogi is focused on two primary therapeutic areas including 1) infectious diseases and 2) pain/CNS disorders.
The partnership centers on Akili’s digital medicines known as AKL-T01 and AKL-T02 in Japan and Taiwan. AKL-T01 is currently under review with the U.S. Food and Drug Administration (FDA) as a potential digital treatment for children with attention-deficit/hyperactivity disorder (ADHD); AKL-T02 is currently in late stage development as a potential digital treatment for cognitive dysfunction and related symptoms in children with Autism Spectrum Disorder (ASD). The digital treatments are delivered through immersive action video game experiences.